Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259454 | 1.00 | LMNA (0.30) | LMNA | |
| SCHEMBL22292169 | 0.82 | ALDH1A1 (0.30) | — | |
| SCHEMBL18657388 | 0.82 | ALDH1A1 (0.30) | — | |
| SCHEMBL18636925 | 0.81 | — | — | |
| SCHEMBL18389724 | 0.80 | LMNA (0.30) | LMNA | |
| SCHEMBL2737129 | 0.80 | ALDH1A1 (0.35) | — | |
| SCHEMBL28298539 | 0.80 | LMNA (0.30) | LMNA | |
| SCHEMBL28773027 | 0.78 | ALDH1A1 (0.33) | — | |
| SCHEMBL27092734 | 0.78 | LMNA (0.35) | LMNA | |
| SCHEMBL26517720 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024071860-A1 | INK COMPOSITION, ORGANIC LIGHT-EMITTING DEVICE USING SAME, AND MANUFACTURING METHOD THEREFOR | 주식회사 엘지화학 | 2024-04-04 | — | — | WO | disclosed |
| US-10668090-B2 | Liver specific delivery-based antiviral prodrug nucleoside cyclophosphate compound and uses thereof | ZHEJIANG PALO ALTO PHARMACEUTICALS, INC (CN) | 2020-06-02 | — | — | US | disclosed |
| EP-3604381-A1 | THERMOPLASTIC LIQUID CRYSTAL POLYMER AND FILM OF SAME | Kuraray Co., Ltd. (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-20190125771-A1 | LIVER SPECIFIC DELIVERY-BASED ANTIVIRAL PRODRUG NUCLEOSIDE CYCLOPHOSPHATE COMPOUND AND USES THEREOF | ZHEJIANG PALO ALTO PHARMACEUTICALS,INC (CN) | 2019-05-02 | — | — | US | disclosed |
| US-20170137384-A1 | PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF | ALCON INC. (CH) | 2017-05-18 | — | — | US | disclosed |
| US-20170049765-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMMAVE THERAPEUTICS SA (CH) | 2017-02-23 | — | — | US | disclosed |
| US-9556294-B2 | Magnetic particle-polymer hybrid materials with functionalized polymers derived from norbornenyl reagents | THE UNIVERSITY OF KANSAS (US) | 2017-01-31 | — | — | US | disclosed |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2017-01-26 | — | — | US | disclosed |
| US-9463170-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9453037-B2 | Methylphenidate-prodrugs, processes of making and using the same | KEMPHARM, INC (US) | 2016-09-27 | — | — | US | disclosed |
| US-9050292-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140243291-A1 | METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME | COMMAVE THERAPEUTICS SA (CH) | 2014-08-28 | — | — | US | disclosed |
| US-8714088-B2 | Lithographic printing plate precursor and lithographic printing method | FUJIFILM CORPORATION (JP) | 2014-05-06 | — | — | US | disclosed |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8426102-B2 | Lithographic printing plate precursor and plate making method | FUJIFILM CORPORATION (JP) | 2013-04-23 | — | — | US | disclosed |
| EP-2404890-A1 | Hydroxyl compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2011145035-A1 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | INDIAN INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-11-24 | — | — | WO | disclosed |
| WO-2010132852-A2 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-2011643-B1 | Planographic printing plate precursor and printing method using the same | FUJIFILM CORP (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-20080119517-A1 | COMPOSITIONS AND METHODS FOR PROTECTING AGAINST MITOCHONDRIA COMPONENT-MEDIATED PATHOLOGY | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137384-A1 | PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF | MAP3K1, MAP3K6, MAP3K7 | LMNA 1106/4885 |
| US-20190125771-A1 | LIVER SPECIFIC DELIVERY-BASED ANTIVIRAL PRODRUG NUCLEOSIDE CYCLOPHOSPHATE COMPOUND AND USES THEREOF | SLC10A1, NPC1, NPC1L1 | LMNA 2438/4885 |
| US-20140243291-A1 | METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME | COMT, PNMT, SLC6A3 | LMNA 4331/4885 |
| US-20170049765-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMT, TPMT, PNMT | LMNA 4533/4885 |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | LMNA 3720/4885 |
| US-10668090-B2 | Liver specific delivery-based antiviral prodrug nucleoside cyclophosphate compound and uses thereof | SLC10A1, NPC1, NPC1L1 | LMNA 2438/4885 |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | LMNA 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.